These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 1286560)
1. Leukocyte-reduced blood components in transfusion medicine. Current indications and prospects for the future. Klapper EB; Goldfinger D Clin Lab Med; 1992 Dec; 12(4):711-21. PubMed ID: 1286560 [TBL] [Abstract][Full Text] [Related]
2. The use of leukocyte-reduced blood components. Miller JP; Mintz PD Hematol Oncol Clin North Am; 1995 Feb; 9(1):69-90. PubMed ID: 7737945 [TBL] [Abstract][Full Text] [Related]
3. Guidelines on the clinical use of leucocyte-depleted blood components. British Committee for Standards in Haematology, Blood Transfusion Task Force. Transfus Med; 1998 Mar; 8(1):59-71. PubMed ID: 9569462 [No Abstract] [Full Text] [Related]
4. From leukocyte reduction to leukocyte transfusion: the immunological effects of transfused leukocytes. Lee JH; Klein HG Baillieres Best Pract Res Clin Haematol; 2000 Dec; 13(4):585-600. PubMed ID: 11102278 [TBL] [Abstract][Full Text] [Related]
5. Dual reduction in the immunologic and infectious complications of transfusion by filtration/removal of leukocytes from donor blood soon after collection. Rawal BD; Davis RE; Busch MP; Vyas GN Transfus Med Rev; 1990 Oct; 4(4 Suppl 1):36-41. PubMed ID: 2134639 [No Abstract] [Full Text] [Related]
8. Leukocyte depletion of cellular blood components. Lane TA Curr Opin Hematol; 1994 Nov; 1(6):443-51. PubMed ID: 9371321 [TBL] [Abstract][Full Text] [Related]
9. Effect of pathogen inactivation on the storage lesion in red cells and platelet concentrates. Seghatchian J; Hervig T; Putter JS Transfus Apher Sci; 2011 Aug; 45(1):75-84. PubMed ID: 21782517 [TBL] [Abstract][Full Text] [Related]
10. Transfusion medicine 1994. Pineda A; Korbling M; Rock GA Rev Invest Clin; 1994 Apr; Suppl():101-15. PubMed ID: 7886293 [No Abstract] [Full Text] [Related]
11. New technologies for the inactivation of infectious pathogens in cellular blood components and the development of platelet substitutes. Corash L Baillieres Best Pract Res Clin Haematol; 2000 Dec; 13(4):549-63. PubMed ID: 11102276 [TBL] [Abstract][Full Text] [Related]
12. [Transfusion of blood and blood derivatives. Measurements of safety, circulatory, immunologic and infectious risks and accidents]. Rouger P; Hergon E Rev Prat; 1997 Sep; 47(13):1499-504. PubMed ID: 9339033 [No Abstract] [Full Text] [Related]
17. Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease. Corash L; Lin L Bone Marrow Transplant; 2004 Jan; 33(1):1-7. PubMed ID: 14647263 [TBL] [Abstract][Full Text] [Related]
18. Biologic effects of leukocytes present in transfused cellular blood products. Bordin JO; Heddle NM; Blajchman MA Blood; 1994 Sep; 84(6):1703-21. PubMed ID: 8080981 [TBL] [Abstract][Full Text] [Related]
19. [Importance and indications for leukocyte-free blood products]. Jullien AM Nouv Rev Fr Hematol (1978); 1993 Jun; 35(3):211-3. PubMed ID: 8337129 [No Abstract] [Full Text] [Related]